155 related articles for article (PubMed ID: 2649324)
1. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabetes Care; 1989 Feb; 12(2):115-9. PubMed ID: 2649324
[TBL] [Abstract][Full Text] [Related]
2. Human isophane or lente insulin? A double blind crossover trial in insulin dependent diabetes mellitus.
Gibb DM; Foot AB; May B; Parish H; Strang S; Grant DB; Dunger DB
Arch Dis Child; 1990 Dec; 65(12):1334-7. PubMed ID: 2270941
[TBL] [Abstract][Full Text] [Related]
3. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM.
Wolfsdorf JI; Laffel LM; Pasquarello C; Vernon A; Herskowitz RD
Diabetes Care; 1991 Nov; 14(11):1100-6. PubMed ID: 1797498
[TBL] [Abstract][Full Text] [Related]
4. A comparison of human ultralente- and lente-based twice-daily injection regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-acting insulin preparations: NPH and lente.
Deckert T
Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
[TBL] [Abstract][Full Text] [Related]
6. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
7. The contribution of intermediate-acting insulin preparations to daytime insulin treatment.
Robert JJ; Chevenne D; Debray M
Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136
[TBL] [Abstract][Full Text] [Related]
8. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
Olsson PO; Hans A; Henning VS
Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.
Pieber TR; Eugène-Jolchine I; Derobert E
Diabetes Care; 2000 Feb; 23(2):157-62. PubMed ID: 10868824
[TBL] [Abstract][Full Text] [Related]
10. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus.
Chase HP; Arslanian S; White NH; Tamborlane WV
J Pediatr; 2008 Oct; 153(4):547-53. PubMed ID: 18589448
[TBL] [Abstract][Full Text] [Related]
11. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
Home P; Bartley P; Russell-Jones D; Hanaire-Broutin H; Heeg JE; Abrams P; Landin-Olsson M; Hylleberg B; Lang H; Draeger E;
Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
[TBL] [Abstract][Full Text] [Related]
12. Different daily blood glucose control and free insulin levels during treatment with mixtures of soluble and lente or soluble and NPH semisynthetic human insulins.
Cucinotta D; Di Benedetto A; Gigante A; Di Cesare E; Musolino C; Squadrito G
Diabete Metab; 1989; 15(4):182-7. PubMed ID: 2680669
[TBL] [Abstract][Full Text] [Related]
13. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
14. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
15. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study.
Taylor R; Davies R; Fox C; Sampson M; Weaver JU; Wood L
Diabetes Care; 2000 Nov; 23(11):1612-8. PubMed ID: 11092282
[TBL] [Abstract][Full Text] [Related]
16. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
17. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
Standl E; Lang H; Roberts A
Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
[TBL] [Abstract][Full Text] [Related]
18. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
[TBL] [Abstract][Full Text] [Related]
19. Comparison of lente insulin and NPH insulin therapy for the treatment of newly diagnosed diabetic dogs: a randomised study.
Fracassi F; Linari G; Del Baldo F; Di Cunzolo A; D'Angelo S; Malerba E; Carotenuto G; Bonfanti U; Corradini S
Vet Rec; 2018 Sep; 183(8):262. PubMed ID: 30030413
[TBL] [Abstract][Full Text] [Related]
20. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
